| 30.13 0.41 (1.38%) | 06-15 09:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 37.8 | 1-year : | 44.15 |
| Resists | First : | 32.36 | Second : | 37.8 |
| Pivot price | 28.11  |
|||
| Supports | First : | 28.43 |
Second : | 26 |
| MAs | MA(5) : | 28.53 |
MA(20) : | 28.37 |
| MA(100) : | 22.74 |
MA(250) : | 20.81 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 51.9 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 32.36 | Low : | 12.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ URGN ] has closed below upper band by 12.7%. Bollinger Bands are 17% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.32 - 31.44 | 31.44 - 31.53 |
| Low: | 29.02 - 29.16 | 29.16 - 29.27 |
| Close: | 29.51 - 29.73 | 29.73 - 29.9 |
UroGen Pharma Ltd. is a biotechnology firm dedicated to creating and marketing innovative treatments for specialized cancers and diseases affecting the urinary tract. Its proprietary technology includes RTGel, a biocompatible polymer with reverse thermal gelation properties designed to enhance the efficacy of existing medications. The company also markets Jelmyto, used in pyelocalyceal solutions. A key component of its pipeline is UGN-102, currently undergoing Phase III clinical trials. This investigational drug targets various forms of non-muscle invasive urothelial cancer, specifically low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Additionally, UroGen is developing UGN-301 for high-grade non-muscle invasive bladder cancer. The company holds a licensing agreement with Allergan Pharmaceuticals International Limited, enabling the development and commercialization of pharmaceutical products incorporating both RTGel and clostridial toxins. It also partners with Agenus Inc. to advance, produce, and commercialize Agenus's products for intravesical delivery in urinary tract cancer treatment. Furthermore, a strategic research collaboration with MD Anderson aims to progress experimental treatments for high-grade bladder cancer. Established in 2004, UroGen Pharma Ltd. operates out of Princeton, New Jersey.
Fri, 12 Jun 2026
URGN Stock Price, Quote & Chart - ChartMill
Tue, 09 Jun 2026
UroGen Pharma (URGN) CMO nets shares as RSUs vest and 5,222 sold for tax - Stock Titan
Tue, 09 Jun 2026
Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144 - Stock Titan
Tue, 09 Jun 2026
How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story - simplywall.st
Mon, 08 Jun 2026
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth - ChartMill
Mon, 08 Jun 2026
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 100.5 (%) |
| Shares Short | 6,920 (K) |
| Shares Short P.Month | 7,240 (K) |
| EPS | -2.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.55 |
| Profit Margin | -94.9 % |
| Operating Margin | -39.8 % |
| Return on Assets (ttm) | -27 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 151.6 % |
| Gross Profit (p.s.) | 2.59 |
| Sales Per Share | 2.88 |
| EBITDA (p.s.) | -2.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -166 (M) |
| Levered Free Cash Flow | -109 (M) |
| PE Ratio | -10.85 |
| PEG Ratio | 0 |
| Price to Book value | -11.66 |
| Price to Sales | 10.3 |
| Price to Cash Flow | -8.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|